Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723236 · ClinicalTrials.gov registry record · Phase 1
A Study of MGC028 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma, sponsored by MacroGenics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 6
- Study locations
NCT06723236 is a Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 124 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06723236, a Phase 1 study of Advanced Solid Tumors and Cholangiocarcinoma, is actively recruiting participants, sponsored by MacroGenics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
Conditions Studied
Interventions
- BIOLOGICAL MGC028
Study Locations (6)
California
- UCSF - Helen Diller Family Cancer Center - San Francisco
Massachusetts
- Dana Farber/Harvard Cancer Center - Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
New York
- Icahn School of Medicine at Mt. Sinai - New York
Texas
- South Texas Accelerated Research Therapeutics (START) San Antonio - San Antonio
Utah
- South Texas Accelerated Research Therapeutics (START) Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723236
The ClinicalTrials.gov registry entry for NCT06723236 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (37% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MGC028 is the first listed.
NCT06723236 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06723236 about?
NCT06723236 is a clinical study titled "A Study of MGC028 in Participants With Advanced Solid Tumors". The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally adv...
What is the current status of trial NCT06723236?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2025-02-13. Estimated completion is 2027-04.
What conditions does trial NCT06723236 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Cholangiocarcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, NSCLC Adenocarcinoma.
What interventions are being tested in trial NCT06723236?
The interventions under investigation include: MGC028 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06723236?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723236 being conducted?
This trial has 6 study locations across California, Massachusetts, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.